Trials / Completed
CompletedNCT02565615
Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting
ATORVASTATIN EFFECTIVENESS AND SAFETY IN CARDIOLOGY PATIENTS IN REAL WORLD SETTING: A REGISTRY STUDY IN CHINA
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,115 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is to verify atorvastatin effectiveness and safety in Chinese population, and explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD。
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | Because this is a non-interventional study, there is no intervention here. |
Timeline
- Start date
- 2016-06-22
- Primary completion
- 2018-08-31
- Completion
- 2018-08-31
- First posted
- 2015-10-01
- Last updated
- 2021-02-21
- Results posted
- 2019-11-04
Locations
54 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02565615. Inclusion in this directory is not an endorsement.